Fortress Biotech (FRA:CNB1) Total Liabilities : €155.10 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Fortress Biotech Total Liabilities?

Fortress Biotech's Total Liabilities for the quarter that ended in Mar. 2024 was €155.10 Mil.

Fortress Biotech's quarterly Total Liabilities declined from Sep. 2023 (€153.47 Mil) to Dec. 2023 (€152.17 Mil) but then increased from Dec. 2023 (€152.17 Mil) to Mar. 2024 (€155.10 Mil).

Fortress Biotech's annual Total Liabilities increased from Dec. 2021 (€151.00 Mil) to Dec. 2022 (€230.60 Mil) but then declined from Dec. 2022 (€230.60 Mil) to Dec. 2023 (€152.17 Mil).

Fortress Biotech Total Liabilities Historical Data

The historical data trend for Fortress Biotech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech Total Liabilities Chart

Fortress Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

138.50

112.13

151.00

230.60

152.17

Fortress Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															227.66	181.52	153.47	152.17	155.10

Fortress Biotech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Fortress Biotech's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	77.861	+	(72.57	+	1.735
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	152.17

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	153.621	-	1.455
	=	152.17

Fortress Biotech's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	80.68	+	(72.716	+	1.699
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	155.10

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	151.473	-	-3.622
	=	155.10

Fortress Biotech Total Liabilities Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Fortress Biotech (FRA:CNB1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (FRA:CNB1) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

FBIOP.PFD:USA FBIO:USA CNB0.PFD:Germany

Address

1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154

Website

https://www.fortressbiotech.com

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Fortress Biotech (FRA:CNB1) Headlines

No Headlines